UNSPSC 51111773: Vinzolidine

This classification denotes a vinca-site binding agent with the molecular formula C48H58ClN5O9, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 533U947V6Q, chemically known as 2h-3,7-methanoazacycloundecino(5,4-b)indole-9-carboxylic acid, 9-((2beta,3beta,4beta,5alpha,12beta,19alpha)-4-(acetyloxy)-3-(2-chloroethyl)-6,7-didehydro-16-methoxy-1-methyl-2,4-dioxospiro(aspidospermidine-3,5-oxazolidin)-15-yl)-5-ethyl-1,4,5,6,7,8,9,10-octahydro-5-hydroxy-, methyl ester, (3r-(3r*,5s*,7r*,9s*))- but generally known as vinzolidine, which bears US NIH Compound Identifier 49966.

UNSPSC 51111773 Vinzolidine, a Commodity code, does not reflect the actual pharmaceutical procurement activity posted under it in recent state and local opportunities. The two recorded opportunities—a completed Illinois Department of Public Health piggyback award for antibiotics (Doxycycline Hyclate and Ciprofloxacin Hydrochloride) and a Seminole County, Florida IFB for Naloxone and drug deactivation systems—involve emergency-response and infectious-disease medications, not vinzolidine, an antibiotic used primarily for resistant gram-positive infections. This misalignment suggests either a data-entry error in the source system or a mislabeling of opportunities at intake. The issuing bodies soliciting under this code span state health departments and county public-health authorities, reflecting the emergency and public-health focus of the medications being procured.

Recent activity appears limited to two opportunities across Florida and Illinois, with no indication of broader geographic spread or repeat solicitation patterns under this code. The Illinois Department of Public Health awarded a $2,999,999.11 three-year piggyback contract through the MMCAP Infuse consortium to Chartwell Rx LLC on August 28, 2026, for antibiotic supply under Bid Number 26-482DPH-PREPD-B-53392—a completed IFB with no open bidding window. Seminole County issued IFB 60459723LAS on June 30, 2026, with a response deadline of July 26, 2026 (note: the summary flags this as a past date relative to posting), seeking annual delivery of 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems on a two-year initial term with renewal option. No active solicitations under this code are currently open.